10 results on '"Li, Xiaoting"'
Search Results
2. Destruction of the cellular antioxidant pool contributes to resveratrol‐induced senescence and apoptosis in lung cancer.
- Author
-
Liang, Chunhua, Yi, Kefan, Zhou, Xu, Li, Xiaoting, Zhong, Caiyun, Cao, Hui, Xie, Chunfeng, and Zhu, Jianyun
- Abstract
Resveratrol (RES) has various pharmacological bioactivities and its anticancer effects in lung cancer have been proven. However, the underlying mechanisms of action of RES in lung cancer remain unclear. This study focused on Nrf2‐mediated antioxidant systems in RES‐treated lung cancer cells. A549 and H1299 cells were treated with various concentrations of RES at different times. RES decreased cell viability, inhibited cell proliferation, and increased the number of senescent and apoptotic cells in a concentration‐ and time‐dependent manner. Moreover, RES‐induced lung cancer cell arrest at the G1 phase was accompanied by changes in apoptotic proteins (Bax, Bcl‐2, and cleaved caspase 3). Furthermore, RES induced a senescent phenotype along with changes in senescence‐related markers (senescence‐associated β‐galactosidase activity, p21, and p‐γH2AX). More importantly, with prolonged exposure time and increased exposure concentration, intracellular reactive oxygen species (ROS) continuously accumulated, resulting in a decrease in Nrf2 and its downstream antioxidant response elements, including CAT, HO‐1, NQO1, and SOD1. Meanwhile, RES‐induced ROS accumulation and cell apoptosis were reversed by N‐acetyl‐l‐cysteine treatment. Taken together, these results suggest that RES disturb lung cancer cellular homeostasis by destroying the intracellular antioxidant pool to increase ROS production. Our findings provide a new perspective on RES intervention in lung cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
3. Correction to: Apatinib triggers autophagic and apoptotic cell death via VEGFR2/STAT3/PD-L1 and ROS/Nrf2/p62 signaling in lung cancer.
- Author
-
Xie, Chunfeng, Zhou, Xu, Liang, Chunhua, Li, Xiaoting, Ge, Miaomiao, Chen, Yue, Yin, Juan, Zhu, Jianyun, and Zhong, Caiyun
- Subjects
CELL death ,LUNG cancer - Abstract
An amendment to this paper has been published and can be accessed via the original article. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
4. Apatinib triggers autophagic and apoptotic cell death via VEGFR2/STAT3/PD-L1 and ROS/Nrf2/p62 signaling in lung cancer.
- Author
-
Xie, Chunfeng, Zhou, Xu, Liang, Chunhua, Li, Xiaoting, Ge, Miaomiao, Chen, Yue, Yin, Juan, Zhu, Jianyun, and Zhong, Caiyun
- Subjects
CELL death ,LUNG cancer ,NON-small-cell lung carcinoma ,APATINIB - Abstract
Background: Recently, a variety of clinical trials have shown that apatinib, a small-molecule anti-angiogenic drug, exerts promising inhibitory effects on multiple solid tumors, including non-small cell lung cancer (NSCLC). However, the underlying molecular mechanism of apatinib on NSCLC remains unclear. Methods: MTT, EdU, AO/EB staining, TUNEL staining, flow cytometry, colony formation assays were performed to investigate the effects of apatinib on cell proliferation, cell cycle distribution, apoptosis and cancer stem like properties. Wound healing and transwell assays were conducted to explore the role of apatinib on migration and invasion. The regulation of apatinib on VEGFR2/STAT3/PD-L1 and ROS/Nrf2/p62 signaling were detected. Furthermore, we collected conditioned medium (CM) from A549 and H1299 cells to stimulate phorbol myristate acetate (PMA)-activated THP-1 cells, and examined the effect of apatinib on PD-L1 expression in macrophages. The Jurkat T cells and NSCLC cells co-culture model was used to assess the effect of apatinib on T cells activation. Subcutaneous tumor formation models were established to evaluate the effects of apatinib in vivo. Histochemical, immunohistochemical staining and ELISA assay were used to examine the levels of signaling molecules in tumors. Results: We showed that apatinib inhibited cell proliferation and promoted apoptosis in NSCLC cells in vitro. Apatinib induced cell cycle arrest at G1 phase and suppressed the expression of Cyclin D1 and CDK4. Moreover, apatinib upregulated Cleaved Caspase 3, Cleaved Caspase 9 and Bax, and downregulated Bcl-2 in NSCLC cells. The colony formation ability and the number of CD133 positive cells were significantly decreased by apatinib, suggesting that apatinib inhibited the malignant and stem-like features of NSCLC cells. Mechanistically, apatinib inhibited PD-L1 and c-Myc expression by targeting VEGFR2/STAT3 signaling. Apatinib also inhibited PD-L1 expression in THP-1 derived macrophages stimulated by CM from NSCLC cells. Furthermore, apatinib pretreatment increased CD69 expression and IFN-γ secretion in stimulated Jurkat T cells co-cultured with NSCLC cells. Apatinib also promoted ROS production and inhibited Nrf2 and p62 expression, leading to the autophagic and apoptotic cell death in NSCLC. Moreover, apatinib significantly inhibited tumor growth in vivo. Conclusion: Our data indicated that apatinib induced autophagy and apoptosis in NSCLC via regulating VEGFR2/STAT3/PD-L1 and ROS/Nrf2/p62 signaling. Highlights: Apatinib suppressed proliferation, induced cell cycle arrest and apoptosis, and inhibited malignancy in NSCLC in vitro and in vivo. Apatinib downregulated PD-L1 and c-Myc in NSCLC through VEGFR2/STAT3 pathway. Apatinib inhibited PD-L1 expression in THP-1 derived macrophages stimulated by the conditioned medium from NSCLC cells and partially restored the activation of Jurkat T cells co-cultured with NSCLC cells. Apatinib induced ROS generation and inhibited Nrf2 and p62 expression, leading to the autophagic and apoptotic cell death in NSCLC. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
5. Identification of Clonal Neoantigens Derived From Driver Mutations in an EGFR -Mutated Lung Cancer Patient Benefitting From Anti-PD-1.
- Author
-
Wu, Di, Liu, Yangyang, Li, Xiaoting, Liu, Yiying, Yang, Qifan, Liu, Yuting, Wu, Jingjing, Tian, Chen, Zeng, Yulan, Zhao, Zhikun, Xiao, Yajie, Gu, Feifei, Zhang, Kai, Hu, Yue, and Liu, Li
- Subjects
EPIDERMAL growth factor receptors ,LUNG cancer ,PROGRAMMED cell death 1 receptors ,CANCER patients ,NON-small-cell lung carcinoma ,PROTEIN-tyrosine kinases ,PAROXYSMAL hemoglobinuria - Abstract
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have been recommended as the first-line therapy for non-small cell lung cancer (NSCLC) patients harboring EGFR mutations. However, acquired resistance to EGFR-TKIs is inevitable. Although immune checkpoint blockades (ICBs) targeting the programmed cell death 1 (PD-1)/PD-ligand (L)1 axis have achieved clinical success for many cancer types, the clinical efficacy of anti-PD-1/PD-L1 blockades in EGFR mutated NSCLC patients has been demonstrated to be lower than those without EGFR mutations. Here, we reported an advanced NSCLC patient with EGFR driver mutations benefitting from anti-PD-1 blockade therapy after acquiring resistance to EGFR-TKI. We characterized the mutational landscape of the patient with next-generation sequencing (NGS) and successfully identified specific T-cell responses to clonal neoantigens encoded by EGFR exon 19 deletion, TP53 A116T and DENND6B R398Q mutations. Our findings support the potential application of immune checkpoint blockades in NSCLC patients with acquired resistance to EGFR-TKIs in the context of specific clonal neoantigens with high immunogenicity. Personalized immunomodulatory therapy targeting these neoantigens should be explored for better clinical outcomes in EGFR mutated NSCLC patients. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
6. ABCB1 polymorphism predicts the toxicity and clinical outcome of lung cancer patients with taxane‐based chemotherapy.
- Author
-
Zhong, Jia, Guo, Zihan, Fan, Liping, Zhao, Xinghui, Zhao, Bingqing, Cao, Zhigang, Cheng, Linlin, Shi, Yuanyuan, Li, Xiaoting, Zhang, Yanhua, An, Tongtong, Wu, Meina, Wang, Yuyan, Zhuo, Minglei, Li, Jianjie, Yang, Xue, Chen, Hanxiao, Jia, Bo, and Zhao, Jun
- Subjects
ANTINEOPLASTIC agents ,CANCER chemotherapy ,CANCER patients ,DRUG toxicity ,GENETIC polymorphisms ,IMMUNOASSAY ,LUNG tumors ,GENETIC mutation ,FLUORESCENCE in situ hybridization ,RETROSPECTIVE studies ,DATA analysis software - Abstract
Background: Taxane‐based chemotherapy is widely used in lung cancer. ABCB1 have a role in the prediction of treatment response and toxicity of chemotherapy in solid tumors. In this retrospective study, we investigated ABCB1 polymorphism on response and toxicity in taxane‐based chemotherapy in lung cancer patients. Methods: A total of 122 lung cancer patients who received taxane‐based chemotherapy were included in this study. Fluorescence in situ hybridization (FISH) was used for ABCB1 polymorphism detection. Turbidimetric inhibition immunoassay was used for pharmacokinetic analysis. Statistical analysis was performed using SPSS 20.0. Results: The frequency of the ABCB1 2677 site TT/TG/GG genotype was 32.8%, 43.4% and 23.8%, respectively and the frequency of the 3435 sites the TT/TC/CC genotype was 13.9%, 44.3% and 41.8%, respectively. The occurrence of neurotoxicity was higher in patients who had ABCB1 3435 site mutation (TT 88.2%, TC 22.2%, CC 21.6% P = 0.004). There was no significant difference between ABCB1 genotypes with regard to other chemotherapy‐induced toxicity. For non‐small cell lung cancer (NSCLC) patients, those harboring ABCB1 2677 and 3435 site wild‐type patients had longer median progression‐free survival (PFS) in the paclitaxel subgroup (3435 site: TT 3.87 vs. TC 9.50 vs. CC 14.13 months; P < 0.001; 2677 site: TT 4.37 vs. TG 9.73 vs. GG 12.1 months; P = 0.013). The area under the concentration‐time curve (AUC) of 20 patients treated with docetaxel increased for ABCB1 mutation subgroups. Conclusion: ABCB1 mutation is associated with higher neurotoxicity of taxane‐based chemotherapy. It also predicts shorter PFS for NSCLC in paclitaxel‐based treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
7. Curcumin reverses tobacco smoke-induced epithelial-mesenchymal transition by suppressing the MAPK pathway in the lungs of mice.
- Author
-
Liang, Zhaofeng, Wu, Rui, Xie, Wei, Zhu, Mingming, Xie, Chunfeng, Li, Xiaoting, Zhu, Jianyun, Zhu, Weiwei, Wu, Jieshu, Geng, Shanshan, Xu, Wenrong, Zhong, Caiyun, and Han, Hongyu
- Subjects
LUNG cancer ,CARCINOGENS ,CARCINOGENICITY ,OBESITY - Abstract
Tobacco smoke is a major risk factor for lung cancer. Epithelial-mesenchymal transition (EMT) is decisive in cancer invasion and metastasis, and therefore promotes cancer progression. Mitogen-activated protein kinase (MAPK) pathways are implicated in various aspects of cancer development and progression, including the EMT process. The chemopreventive effect of curcumin on carcinogenesis has been reported in vivo and in vitro. The present study investigated tobacco smoke-induced alterations in the MAPK/activator protein-1 (AP-1) pathways, and pulmonary EMT changes in the lungs of mice, and further observed the chemopreventive effect of curcumin. The protein expression levels analyzed by western blot analysis demonstrated that 12 weeks of tobacco smoke exposure activated extracellular-signal-regulated kinase (ERK) 1/2, c-Jun N-terminal kinase (JNK) and p38 MAPK pathways, in addition to AP-1, in the lungs of mice, while reducing the activation of ERK5/MAPK pathways. The results also indicated that the mRNA and protein levels of the epithelial markers E-cadherin and zona occludens-1 were reduced following tobacco smoke exposure. Conversely, the expression levels of mRNA and protein for the mesenchymal markers vimentin and N-cadherin were increased. Curcumin treatment inhibited tobacco smoke-induced MAPK/AP-1 activation, including ERK1/2, JNK and p38 MAPK pathways, and AP-1 proteins, and reversed EMT alterations in lung tissue. The results of the present study provide new insights into the molecular mechanisms of tobacco smoke-associated lung cancer and may open up new avenues in the search for potential therapeutic targets in lung tumorigenesis. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
8. Diallyl trisulfide induces pyroptosis and impairs lung CSC-like properties by activating the ROS/Caspase 1 signaling pathway.
- Author
-
Xie, Chunfeng, Zhou, Xu, Chen, Weiyi, Ren, Dongxue, Li, Xiaoting, Jiang, Runqiu, Zhong, Caiyun, and Zhu, Jianyun
- Subjects
- *
LUNGS , *PYROPTOSIS , *CASPASES , *CANCER stem cells , *CELLULAR signal transduction , *CELL cycle - Abstract
Lung cancer stem cells (CSCs) drive continuous cancer growth and metastatic dissemination; thus, there is an urgent requirement to acquire effective therapeutic strategies for targeting lung CSCs. Diallyl trisulfide (DATS), a garlic organosulfide, possesses suppressive potential in lung cancer; however, its underlying mechanism is still unclear. In this study, we identified DATS as a pyroptosis inducer in lung cancer cells. DATS-treated A549 and H460 cells exhibited pyroptotic cell death, with characteristic large bubbles appearing on their plasma membrane and LDH release. DATS induced cell death, arrested the cell cycle at the G2/M phase, and inhibited colony formation in lung cancer cells. Meanwhile, we found that DATS significantly suppressed the malignant features by impairing lung CSC-like properties, including sphere formation ability, CD133 positive cell number, and lung CSCs marker expression. Mechanistically, DATS induced cell pyroptosis via increasing the expression of NLRP3, ASC, Pro Caspase 1, Cleaved Caspase 1, GSDMD, GSDMD-N, and IL-1β. The verification experiments showed that the effects of DATS on pyroptosis and lung CSC-like properties were weakened after Caspase 1 inhibitor VX-765 treatment, indicating that DATS activated NLRP3 inflammasome-mediated pyroptosis by targeting Caspase 1 in lung cancer cells. Moreover, DATS increased ROS overproduction and mitochondrial dysfunction, which contributed to DATS-induced pyroptosis of lung cancer cells. NAC treatment reversed the effects of DATS on pyroptosis and CSC-like properties. In vivo experiment further confirmed that DATS restrained tumor growth. Together, our results suggest that DATS promotes pyroptosis and impairs lung CSC-like properties by activating ROS/Caspase 1 signaling pathway, thereby retarding lung cancer progression. • DATS inhibited malignant phenotypes of lung cancer cells by targeting CSCs. • DATS destroyed lung CSC-like properties via inducing cell pyroptosis by targeting Caspase 1. • ROS overproduction enhanced the effects of DATS on cell pyroptosis and lung CSCs. • DATS destroyed lung CSCs to retard lung cancer progression by inducing pyroptosis. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
9. Wnt/β-catenin pathway mediates (−)-Epigallocatechin-3-gallate (EGCG) inhibition of lung cancer stem cells.
- Author
-
Zhu, Jianyun, Jiang, Ye, Yang, Xue, Wang, Shijia, Xie, Chunfeng, Li, Xiaoting, Li, Yuan, Chen, Yue, Wang, Xiaoqian, Meng, Yu, Zhu, Mingming, Wu, Rui, Huang, Cong, Ma, Xiao, Geng, Shanshan, Wu, Jieshu, and Zhong, Caiyun
- Subjects
- *
LUNG cancer , *WNT proteins , *CATENINS , *EPIGALLOCATECHIN gallate , *CANCER stem cells , *CANCER invasiveness - Abstract
Cancer stem cells (CSCs) play essential role in the progression of many tumors. Wnt/β-catenin pathway is crucial in maintaining the stemness of CSCs. (−)-Epigallocatechin-3-gallate (EGCG), the major bioactive component in green tea, has been shown to possess anti-cancer activity. To date, the interventional effect of EGCG on lung CSCs has not been elucidated yet. In the present study, tumorsphere formation assay was used to enrich lung CSCs from A549 and H1299 cells. We revealed that Wnt/β-catenin pathway was activated in lung CSCs, and downregulation of β-catenin, abolished lung CSCs traits. Our study further illustrated that EGCG effectively diminished lung CSCs activity by inhibiting tumorsphere formation, decreasing lung CSCs markers, suppressing proliferation and inducing apoptosis. Moreover, We showed that EGCG downregulated Wnt/β-catenin activation, while upregulation of Wnt/β-catenin dampened the inhibitory effects of EGCG on lung CSCs. Taken together, these results demonstrated the role of Wnt/β-catenin pathway in regulating lung CSCs traits and EGCG intervention of lung CSCs. Findings from this study could provide new insights into the molecular mechanisms of lung CSCs intervention. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
10. Resveratrol suppresses lung cancer by targeting cancer stem-like cells and regulating tumor microenvironment.
- Author
-
Xie, Chunfeng, Liang, Chunhua, Wang, Rong, Yi, Kefan, Zhou, Xu, Li, Xiaoting, Chen, Yue, Miao, Dengshun, Zhong, Caiyun, and Zhu, Jianyun
- Subjects
- *
LUNG cancer , *TUMOR microenvironment , *CANCER cells , *CANCER stem cells , *RESVERATROL , *CELL anatomy - Abstract
Increasing evidence indicate that cancer stem cells (CSCs) are the key driver of tumor initiation and recurrence. The cellular and soluble components of the tumor microenvironment (TME) impact on cancer initiation and progression, such as cytokines and chemokines. Thus, targeting CSCs and TME is a novel anti-cancer approach. Resveratrol (RES), a bioactive phytochemical extracted from various plants, exhibits tumor-suppressing activities in lung cancer, yet the mechanism remains poorly understood. Our data showed that the expression level of IL-6 was positively correlated with the presence of lung cancer stem-like cells (LCSCs) in human lung cancer tissues. In vitro results showed that IL-6 was highly elevated in lung cancer sphere-forming cells and could enhance the stemness of LCSCs, including tumor sphere formation ability, the percentage of CD133 positive cells, and the expression of LCSC specific markers (CD133, ALDH1A1 and Nanog). Simultaneously, our results confirmed that RES effectively inhibited LCSC properties, downregulated Wnt/β-catenin signaling and reduced IL-6 level in vitro and in vivo. Furthermore, we found RES treatment attenuated the activation of Wnt/β-catenin signaling by LiCl (GSK3β agonist). IL-6-promoted LCSC properties and Wnt/β-catenin signaling was also reversed by RES. Taken together, these data illustrated that RES inhibited lung cancer by targeting LCSCs and IL-6 in TME. The novel findings from this study provided evidence that RES exhibited multi-target effects on suppression of lung cancer and could be a novel potent cancer-preventive compound. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.